Articles tagged with Transforming Growth Factor
Researchers have discovered an inactive form of scatter factor protein that effectively suppresses tumor growth and dissemination in mice. The study provides promising insights into the development of new cancer therapies.
A researcher is studying how tumors pirate angiogenesis, the formation of new blood vessels, to survive. Dr. Motamed focuses on protein SPARC, which regulates growth factors and has multiple roles in cancer and new blood vessel formation.
Researchers found that c-Myc is essential for tumor development by regulating blood vessel growth. The study suggests disrupting c-Myc may be a successful anti-angiogenic tool in cancer therapy, targeting tumors' vascular networks to slow growth.
A crucial molecular dance has been identified as the primary driver of pulmonary fibrosis, an incurable lung inflammation. Researchers discovered that a protein called integrin activates TGF Beta, leading to excessive fibrous scarring in lungs.
Scientists at Max Planck Institute have developed a non-invasive method to supply diseased hearts with vessel growth promoting factors, using microscopic beads that slowly release growth factor over 7 days. The treatment is suitable for small vessels but not large stenosing coronary vessels.
Research on plasminogen-related growth factors has shed light on their role in mammalian development, tumorigenesis, and angiogenesis. The symposium explores the evolution of these growth factors and their interactions with other molecules, highlighting their importance in various biological processes.
Scientists have identified a new factor regulating lymphatic vessel growth, which may lead to ways of repairing damaged vessels and better understanding of certain types of cancer. The discovery of VEGF-C could also improve healing after lymph node removal in breast cancer surgery or prevent tumors affecting the lymphatic system.
Researchers found that polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor (MGDF) significantly increased platelet counts in patients with advanced non-small-cell lung cancer after chemotherapy. Platelet counts returned to normal within 14 days, faster than in placebo recipients.